Subudhi, Sonu http://orcid.org/0000-0002-5937-1880
Verma, Ashish http://orcid.org/0000-0001-9497-6327
Patel, Ankit B. http://orcid.org/0000-0001-6812-1464
Hardin, C. Corey
Khandekar, Melin J. http://orcid.org/0000-0002-9033-3241
Lee, Hang
McEvoy, Dustin http://orcid.org/0000-0002-5860-1541
Stylianopoulos, Triantafyllos
Munn, Lance L. http://orcid.org/0000-0003-0698-7232
Dutta, Sayon http://orcid.org/0000-0002-0381-6860
Jain, Rakesh K. http://orcid.org/0000-0001-7571-3548
Article History
Received: 27 October 2020
Accepted: 16 April 2021
First Online: 21 May 2021
Competing interests
: LLM owns equity in Bayer AG and is a consultant for SimBiosys. R.K.J. received honorarium from Amgen; consultant fees from Chugai, Elpis, Merck, Ophthotech, Pfizer, SPARC, SynDevRx, XTuit; owns equity in Accurius, Enlight, Ophthotech, SynDevRx; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund; and received a grant from Boehringer Ingelheim. Neither any reagent nor any funding from these organizations was used in this study. Other coauthors have no conflict of interests to declare.